Dissecting these differential outcomes shaped by tumor type, immune status, BET protein specificity, and treatment dynamics is essential for the rational design of BET-targeted therapies that harness, rather than hinder, NK cell–mediated anti-tumor immunity. This evidence concerns the gene DNER and neoplasm.